• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Cell MedX Moves Production to Canada

    Bryan Mc Govern
    Apr. 26, 2017 08:37AM PST
    Biotech Investing

    Cell MedX announced its Canadian subsidiary signed a production agreement with a manufacturing facility in British Columbia.

    Cell MedX (OTCQB:CMXC) announced its Canadian subsidiary signed a production agreement, effectively moving manufacturing duties to a facility in British Columbia.
    As quoted in the press release:

    The move is intended to allow the Company to facilitate its planned distribution under the current registration with the U.S. Food and Drug Administration while ensuring lower production costs and greater control of the manufacturing and distribution process. Furthermore, it will assist the Company with setting up its standard operating procedures under ISO 13485-2016, a requirement by Health Canada to register the Company’s eBalance Pro device as Class II medical device.
    Mr. McEnulty, the Company’s CEO, stated: “Our team is very excited to continue moving ahead with our strategic plan. The new relationships that we secured with both the manufacturing facility as well as with our new suppliers is the next essential step to bring our eBalance Pro device to market.”

    Click here to read the full press release.

    Source: www.accesswire.com

    canadian subsidiaryfood and drug administrationcanadabritish columbia
    The Conversation (0)

    Go Deeper

    AI Powered
    Biotech therapy capsule containing DNA strand surrounded by cells.

    Top 5 Canadian Biotech Stocks of 2025

    Canada maple leaves on left and pharmaceutical pills in red and blue on right.

    5 Best-performing Canadian Pharma Stocks of 2025

    Latest News

    Orphan Drug Designation Granted by U.S. FDA for Anal Cancer

    Trading Halt

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×